Ultragenyx Pharmaceutical (RARE) Non Operating Investment Income (2019 - 2025)
Ultragenyx Pharmaceutical (RARE) posted quarterly Non Operating Investment Income of $678000.0 for Q3 2025, little changed year-over-year from $678000.0 in Q3 2024, and up 7633.33% quarter-over-quarter from -$9000.0 in Q2 2025.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Non Operating Investment Income (2019 - 2025) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Non Operating Investment Income for 7 consecutive years, with $678000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Non Operating Investment Income changed 0.0% year-over-year to $678000.0; the TTM figure through Sep 2025 stood at -$1.0 million (down 144.62% YoY), while the FY2024 annual figure was -$1.1 million, down 380.86% from the prior year.
- Non Operating Investment Income improved to $678000.0 in Q3 2025 per RARE's latest filing, from -$9000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $25.7 million in Q3 2021 and bottomed at -$31.0 million in Q2 2021.
- Historically, Non Operating Investment Income has averaged -$3.2 million across 5 years, with a median of -$334000.0 in 2023.
- On a YoY basis, Non Operating Investment Income climbed as much as 1221.56% in 2024 and fell as far as 1629.12% in 2024.
- Ultragenyx Pharmaceutical's Non Operating Investment Income stood at -$16.1 million in 2021, then surged by 111.43% to $1.8 million in 2022, then climbed by 2.66% to $1.9 million in 2023, then tumbled by 181.95% to -$1.5 million in 2024, then jumped by 143.8% to $678000.0 in 2025.
- Business Quant data shows RARE's Non Operating Investment Income at $678000.0 in Q3 2025, -$9000.0 in Q2 2025, and -$157000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 678,000.00 |
| Jun 30, 2025 | -9,000.00 |
| Mar 31, 2025 | -157,000.00 |
| Dec 31, 2024 | -1.55 Mn |
| Sep 30, 2024 | 678,000.00 |
| Jun 30, 2024 | -3.99 Mn |
| Mar 31, 2024 | 3.75 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | 261,000.00 |
| Mar 31, 2023 | -334,000.00 |
| Dec 31, 2022 | 1.84 Mn |
| Sep 30, 2022 | -1.63 Mn |
| Jun 30, 2022 | -10.18 Mn |
| Mar 31, 2022 | -9.33 Mn |
| Dec 31, 2021 | -16.10 Mn |
| Sep 30, 2021 | 25.70 Mn |
| Jun 30, 2021 | -31.05 Mn |
| Mar 31, 2021 | -20.62 Mn |
| Dec 31, 2020 | 79.06 Mn |